This systematic review was performed to summarize the current body of knowledge about the efficacy/effectiveness as well as the safety profile of alpha-1 antagonists in the management of arterial hypertension and LUTS suggestive of BPH in patients ≥ 65 years and to derive recommendations on the use of alpha-1 antagonists in the subgroup of older adults. Here, PSMA6 is linked to benign prostatic hyperplasia.